BRCA2 and breast carcinoma: Finally, the lack of sensitivity to the PARP inhibitor Olaparib observed in our cell lines (Fig. 9c) has important clinical implications as breast cancer patients carrying these variants are not predicted to respond to PARP inhibitor treatment (unlike BRCA2-mutated tumors that are HR-deficient).